Literature DB >> 21346771

Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.

Maxime Chapon1, Clotilde Randriamampita, Eve Maubec, Cécile Badoual, Stéphane Fouquet, Shu-Fang Wang, Eduardo Marinho, David Farhi, Marylène Garcette, Simon Jacobelli, Alexandre Rouquette, Agnès Carlotti, Angélique Girod, Armelle Prévost-Blondel, Alain Trautmann, Marie-Françoise Avril, Nadège Bercovici.   

Abstract

Programmed death-1 (PD-1) is involved in T-cell tolerance to self-antigens. For some cancers, it has been suggested that the expression of a ligand of PD-1, namely PD-L1, could contribute to tumor escape from immune destruction. Nevertheless, the relationship between PD-1 expression on tumor-infiltrating T lymphocytes (TILs), disease stage, and TIL responsiveness is still poorly documented. In this study, we show that freshly isolated CD4(+) and CD8(+) TILs express substantial levels of PD-1 in primary melanomas. The expression of PD-1 was further increased at later stages in distant cutaneous metastases, especially on CD8(+) TILs. The expression of PD-1 ligands was frequent only in metastases, on both tumor cells and tumor-derived myeloid cells. TILs isolated from these cutaneous tumors are poorly reactive ex vivo, with blunted calcium response and IFN-γ production after TCR stimulation. Surprisingly, in distinct parts of a primary melanoma, either invasive or regressing, we show that TILs similarly express PD-1 and remain dysfunctional. The expressions of PD-1 and PD-L1 in metastatic melanoma lesions could be considered as witnesses of an unsuccessful anti-tumoral immune response, but the direct involvement of PD-1 in the severity of the disease, and the importance of TILs in tumor regression, remain to be established.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346771     DOI: 10.1038/jid.2011.30

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  37 in total

1.  Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy.

Authors:  Panagiotis Balermpas; Daniel Martin; Ulrike Wieland; Margret Rave-Fränk; Klaus Strebhardt; Claus Rödel; Emmanouil Fokas; Franz Rödel
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  T cell avidity and tumor immunity: problems and solutions.

Authors:  Arthur A Hurwitz; Steven M Cuss; Katherine E Stagliano; Ziqiang Zhu
Journal:  Cancer Microenviron       Date:  2013-12-20

3.  Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.

Authors:  Zhixue Zheng; Zhaode Bu; Xijuan Liu; Lianhai Zhang; Ziyu Li; Aiwen Wu; Xiaojiang Wu; Xiaojing Cheng; Xiaofang Xing; Hong Du; Xiaohong Wang; Ying Hu; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

4.  Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.

Authors:  Arutselvan Natarajan; Aaron T Mayer; Robert E Reeves; Claude M Nagamine; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

5.  Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer.

Authors:  Ameet A Chimote; Peter Hajdu; Alexandros M Sfyris; Brittany N Gleich; Trisha Wise-Draper; Keith A Casper; Laura Conforti
Journal:  Cancer Res       Date:  2016-11-04       Impact factor: 12.701

6.  Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.

Authors:  Zachary A Cooper; Vikram R Juneja; Peter T Sage; Dennie T Frederick; Adriano Piris; Devarati Mitra; Jennifer A Lo; F Stephen Hodi; Gordon J Freeman; Marcus W Bosenberg; Martin McMahon; Keith T Flaherty; David E Fisher; Arlene H Sharpe; Jennifer A Wargo
Journal:  Cancer Immunol Res       Date:  2014-04-29       Impact factor: 11.151

Review 7.  Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Authors:  D Atanackovic; T Luetkens; N Kröger
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

Review 8.  Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.

Authors:  Lauren C Harshman; Toni K Choueiri; Charles Drake; F Stephen Hodi
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

9.  PD-1 targeting in cancer immunotherapy.

Authors:  Robert Ferris
Journal:  Cancer       Date:  2012-10-05       Impact factor: 6.860

10.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

Authors:  Weiyi Peng; Chengwen Liu; Chunyu Xu; Yanyan Lou; Jieqing Chen; Yan Yang; Hideo Yagita; Willem W Overwijk; Gregory Lizée; Laszlo Radvanyi; Patrick Hwu
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.